Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant

[1]  M. Hammami,et al.  Autologous Graft-Versus-Host Disease of the Gastrointestinal Tract in Patients With Multiple Myeloma and Hematopoietic Stem Cell Transplantation , 2018, Gastroenterology research.

[2]  M. Mapara,et al.  Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies , 2017 .

[3]  M. Camilleri,et al.  Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry. , 2017, Clinical biochemistry.

[4]  P. Oefner,et al.  The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation , 2017, PloS one.

[5]  P. Hari,et al.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Z. Halpern,et al.  A double‐blind, placebo‐controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea‐predominant IBS , 2017, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[7]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[8]  P. Chiusolo,et al.  Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation , 2017, Annals of Hematology.

[9]  D. Burton,et al.  13C mannitol as a novel biomarker for measurement of intestinal permeability , 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[10]  M. Boccadoro,et al.  Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[11]  A. Zinsmeister,et al.  Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea‐predominant irritable bowel syndrome , 2015, Alimentary pharmacology & therapeutics.

[12]  Ankur Gupta,et al.  Outcomes from treating bile acid malabsorption using a multidisciplinary approach , 2015, Supportive Care in Cancer.

[13]  T. Spitzer,et al.  Engraftment syndrome: double-edged sword of hematopoietic cell transplants , 2015, Bone Marrow Transplantation.

[14]  J. Walters,et al.  The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid , 2015, Alimentary pharmacology & therapeutics.

[15]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[16]  Mohid S. Khan,et al.  Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. , 2014, Blood.

[17]  M. Camilleri.  Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms , 2014, The Journal of physiology.

[18]  A. Zinsmeister,et al.  Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  V. Raina,et al.  Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS , 2013, SpringerPlus.

[20]  Stephanie J. Lee,et al.  Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  J. Gribben,et al.  Bile acid malabsorption in patients with graft‐versus‐host disease of the gastrointestinal tract , 2012, British journal of haematology.

[22]  A. Zinsmeister,et al.  Urine sugars for in vivo gut permeability: validation and comparisons in irritable bowel syndrome-diarrhea and controls. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[23]  R. A’Hern,et al.  Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.

[24]  M. Tan,et al.  Rapid Immune Recovery and Graft-versus-Host Disease–like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells , 2009, Clinical Cancer Research.

[25]  M. Camilleri,et al.  Measurement of serum 7α‐hydroxy‐4‐cholesten‐3‐one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography‐tandem mass spectrometry , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[26]  M. Villa,et al.  A liquid chromatography/mass spectrometry method for the evaluation of intestinal permeability. , 2008, Clinical biochemistry.

[27]  B. Angelin,et al.  Monitoring hepatic cholesterol 7α-hydroxylase activity by assay of the stable bile acid intermediate 7α-hydroxy-4-cholesten-3-one in peripheral blood Published, JLR Papers in Press, January 16, 2003. DOI 10.1194/jlr.D200043-JLR200 , 2003, Journal of Lipid Research.

[28]  C. Chang,et al.  Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients , 2003, BMC gastroenterology.

[29]  S. Lewis,et al.  Stool form scale as a useful guide to intestinal transit time. , 1997, Scandinavian journal of gastroenterology.

[30]  A. Hall,et al.  Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. , 1992, Blood reviews.

[31]  A. Hofmann,et al.  The syndrome of ileal disease and the broken enterohepatic circulation: cholerheic enteropathy. , 1967, Gastroenterology.

[32]  M. Pasquini,et al.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  Sung Sook Lee,et al.  BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity , 2007, Annals of Hematology.

[34]  B. Angelin,et al.  Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood. , 2003, Journal of lipid research.

[35]  J. Winter,et al.  Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea , 2002, Bone Marrow Transplantation.

[36]  E. Thomas.  Stem cell transplantation: Past, present and future , 1994, Stem cells.

[37]  D. Small,et al.  Detergent properties of bile salts: correlation with physiological function. , 1967, Annual review of medicine.